Bariatric procedures vs semaglutide costs

A 2026 economic model found that no single obesity treatment was the best-value option in every comparison. From a UK National Health Service perspective, laparoscopic sleeve gastrectomy was cost-effective against endoscopic sleeve gastroplasty for people with class II or III obesity. Endoscopic sleeve gastroplasty, in turn, was cost-effective against semaglutide for the modelled class I and II groups. Semaglutide cost less and produced more health gain than an intragastric balloon^[1]. The findings compare strategies inside a model; they do not show that one intervention is clinically right for every patient.

What the researchers modelled

The investigators built three state-transition Markov models. One compared endoscopic sleeve gastroplasty, or ESG, with laparoscopic sleeve gastrectomy, known as LSG. A second compared ESG with semaglutide. The third compared an intragastric balloon with semaglutide. Patients moved between health states defined by body mass index over five years. Treatment-effect estimates came from published research and expert input rather than from one randomized head-to-head trial^[1].

ESG reshapes the stomach from inside with an endoscope and sutures, without surgically removing part of it. LSG is an operation that removes a large portion of the stomach. An intragastric balloon is placed temporarily to occupy stomach volume. These procedures differ in invasiveness, durability and follow-up needs, so the model compared both costs and health outcomes rather than weight change alone.

How to read cost per QALY

Results were expressed in quality-adjusted life years, or QALYs. One QALY represents one year in full health; shorter life or reduced health-related quality of life contributes less. An incremental cost-effectiveness ratio, or ICER, divides the extra cost of one strategy by its extra QALYs. It is a system-level value measure, not a price quote and not an estimate of what an individual will pay. For background on access and oversight, see our UK regulation hub.

For class II and III obesity, LSG produced an ICER of £10,593 per QALY compared with ESG. For class I and II obesity, ESG generated slightly more QALYs than semaglutide at a modestly higher cost, yielding an ICER of £7,267 per QALY. In the balloon comparison, semaglutide was dominant^[1]. In health economics, dominant means that it generated more health benefit while costing less in the model. It does not mean semaglutide was superior on every clinical outcome.

Why the answer changed by comparator

The three results are not contradictory. Cost-effectiveness is always relative to a specified alternative and population. A surgical option may require more spending at the start yet preserve benefit for longer. A medicine spreads costs over time, while its modelled value depends on how long treatment continues and what happens after it stops. A temporary balloon has a different cost and weight-regain pattern again. Changing the comparator changes both sides of the calculation.

The sensitivity analyses identified intervention cost and assumptions about recurrent weight gain as key drivers^[1]. That is important because five-year projections extend beyond some direct evidence. If a procedure costs more to deliver, or if weight returns faster than assumed, its ICER can worsen. If an effect is more durable, the same upfront expense can be distributed across more health gain. The publication therefore supports conditional conclusions, not a permanent league table.

The NHS context matters

The paper used a UK NHS perspective, so its prices and care pathways should not be exported unchanged to another health system. NICE recommends semaglutide only under defined NHS conditions, alongside dietary change and increased activity, within a specialist weight-management service. Its 2023 appraisal limited use to a maximum of two years and set eligibility criteria around BMI plus weight-related comorbidity^[2]. Those conditions help explain why the model is not a generic comparison of indefinite semaglutide use with a one-off procedure.

NICE separately says ESG can be used for adults with obesity under standard governance, consent and audit arrangements. Selection and monitoring should occur through an experienced multidisciplinary specialist service, and the procedure should be performed in specialist centres by appropriately trained clinicians^[3]. The economic result does not replace those clinical safeguards. Readers can also review the wider semaglutide evidence page before treating one modelled comparison as a complete benefit-risk assessment.

What the study cannot decide

A model can integrate evidence that no single trial contains, but its output is only as reliable as its inputs and structural assumptions. This analysis did not randomly assign the same patients to all four strategies. It cannot determine an individual's operative risk, likely adherence to medication or preference for a reversible approach. Nor can it settle how future prices, service capacity or new evidence will change the comparison.

The useful conclusion is narrower. In this five-year UK analysis, LSG offered good value against ESG for more severe obesity, ESG offered good value against semaglutide in lower modelled BMI classes, and semaglutide outperformed the balloon economically. Those results can inform commissioning discussions. A personal treatment decision still requires a specialist assessment of expected benefit, risks and practical fit.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.